FDA seeks comments on ways to facilitate appropriate opioid prescribing
The Food and Drug Administration seeks stakeholder input on how it might use Risk Evaluation and Mitigation Strategies to facilitate appropriate prescribing of opioid pain relievers. For example, the agency’s Opioid Policy Steering Committee is considering using REMS to require sponsors to ensure that opioid analgesic prescriptions exceeding a certain amount document medical necessity and/or leverage a nationwide prescription history database to prevent misuse or abuse, the FDA notice states. The agency will hold a Jan. 30 public hearing on the issue, with comments accepted through March 16.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services released an updated notice Nov. 20 on the processing of Medicare provider claims impacted by the government…
Headline
The AHA will host a webinar Dec. 18 at 1 p.m. ET on strategies to better protect senior leaders in hospitals. Attendees will learn ways to reduce…
Headline
The Centers for Medicare & Medicaid Services Nov. 21 issued a final rule that, among other provisions, increases Medicare hospital outpatient prospective…
Perspective
Imagine a powerful practice that strengthens human connection, improves well-being, boosts psychological health and supports a healthy workplace culture. And…
Headline
The Centers for Medicare & Medicaid Services will retroactively pay claims for telehealth services provided during the government shutdown through Jan. 30…
Headline
U.S. and international agencies Nov. 19 released a guide on mitigating potential cybercrimes from bulletproof hosting providers. A BPH provider is an internet…